Liposomes for malaria management: the evolution from 1980 to 2020

Abstract

Malaria is one of the most prevalent parasitic diseases and the foremost cause of morbidity in the tropical regions of the world. Strategies for the efficient management of this parasitic infection include adequate treatment with anti-malarial therapeutics and vaccination. However, the emergence and spread of resistant strains of malaria parasites to the majority of presently used anti-malarial medications, on the other hand, complicates malaria treatment. Other shortcomings of anti-malarial drugs include poor aqueous solubility, low permeability, poor bioavailability, and non-specific targeting of intracellular parasites, resulting in high dose requirements and toxic side effects. To address these limitations, liposome-based nanotechnology has been extensively explored as a new solution in malaria management. Liposome technology improves anti-malarial drug encapsulation, bioavailability, target delivery, and controlled release, resulting in increased effectiveness, reduced resistance progression, and fewer adverse effects. Furthermore, liposomes are exploited as immunological adjuvants and antigen carriers to boost the preventive effectiveness of malaria vaccine candidates. The present review discusses the findings from studies conducted over the last 40 years (1980–2020) using in vitro and in vivo settings to assess the prophylactic and curative anti-malarial potential of liposomes containing anti-malarial agents or antigens. This paper and the discussion herein provide a useful resource for further complementary investigations and may pave the way for the research and development of several available and affordable anti-malarial-based liposomes and liposomal malaria vaccines by allowing a thorough evaluation of liposomes developed to date for the management of malaria.

Liposomes as Multifunctional Nano-Carriers for Medicinal Natural Products

“…We only picked up some typical examples from lots of liposomal natural products for the demo (Table 1). Artemisinin, isolated from Artemisia annua L., was discovered in 1972 to treat malaria by Youyou Tu who was awarded the Nobel Prize in physiology or medicine (Figure 2) (Isacchi et al, 2011a;Memvanga and Nkanga, 2021). It also showed activities in chemotherapeutic drug for tumors and lupus erythematosus (Mu and Wang, 2018).…”

An Overview of Herbal-Based Antidiabetic Drug Delivery Systems: Focus on Lipid- and Inorganic-Based Nanoformulations

“…Nanoformulations, i.e., nanoparticlulate systems are colloidal dispersions of very small size ranging from 1 to 1000 nm, with a high surface area in relation to their volume, and whose morphology and properties depend on their components and preparation methods [ 184 , 185 ]. They have several applications, including their use as drug carriers.…”

CRISPR-Cas13 in malaria parasite: Diagnosis and prospective gene function identification

“…Malaria has been a major global health problem for humans throughout their history and is a leading cause of mortality across many tropical and subtropical countries ( Hemingway and Bates, 2003 ; Cowman et al, 2016 ; Monroe et al, 2022 ). Malaria control efforts have been undermined by the decline in the effectiveness of the primary malaria-figurehting tools, increasing resistance to treated-insecticide nets and anti-malarial drugs, and no effective vaccine ( Olotu et al, 2013 ; Haldar et al, 2018 ; Memvanga and Nkanga, 2021 ). Spotlights from the 2022 world malaria report by WHO showed that cases of malaria increased from 245 million in 2020 to 247 million in 2021, although malaria-related deaths slightly decreased from 625,000 to 619,000 ( World Health Organization, 2022 ).…”

“…The etiological agent of malaria, Plasmodium, mainly thrives in human and mosquito hosts. Of all Plasmodium parasites, five species are responsible for global malaria infections in humans: Plasmodium falciparum , Plasmodium vivax , Plasmodium malariae , Plasmodium ovale , and Plasmodium knowlesi ( Lalremruata et al, 2017 ; Memvanga and Nkanga, 2021 ; Sato, 2021 ).…”